SecBot SecBot

SPTX

Seaport Therapeutics, Inc.
Nasdaq· CIK 0002042347 Biotech & Drug Discovery
$20.83 +0.22 (+1.07%)
Oct 26 4:00 PM ET · prev $20.61
Market cap
$1.1B
Small cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
$35.00
+68% · range $28.00–50.00
Since first trade
+5.0%
from $19.84 · May 1
30 days
+6.1%
from $19.64
Range since listing
$15.25–27.84
−25% from high · low May 11
Avg volume 20D
206.9K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$20.0M
2 buyers · 0 sellers · 12 mo
New fund stakes
9
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL Seaport Therapeutics reported Q2 2026 results: net loss of $62.6M ($1.78/share) versus consensus of -$0.71…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $20.0M at an average $18.00. No open-market sales. Price is 16% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 9 added (9 new), 0 trimmed or exited. Largest new: Goldman Sachs Group $47.3M, Canada Pension Plan Investment Board $42.9M.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.567 → −$0.557 over 90 days. 2 up, 1 down in 30 days.

  • TrendDOWNTREND

    3% below its 50-day average.

Who's buying

13F· Q2 2026
9
new positions
0
exits
$249.7M
in new stakes
FundMoveSharesValue
GOLDMAN SACHS GROUP INCNEW2,178,642$47.3M
CANADA PENSION PLAN INVESTMENT BOARDNEW1,975,791$42.9M
JPMORGAN CHASE & CONEW1,815,845$40.9M
PRICE T ROWE ASSOCIATES INC /MD/NEW1,308,604$28.4M
FMR LLCNEW1,185,100$25.7M
JENNISON ASSOCIATES LLCNEW1,079,669$23.5M
RA CAPITAL MANAGEMENT, L.P.NEW700,000$15.2M
VANGUARD CAPITAL MANAGEMENT LLCNEW599,217$13.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy6Buy6Hold2Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +68%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Oct 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 25, 2026Raymond James
INITIATE
INITIATEStrong Buy
Sep 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 26, 2026Jones Trading
INITIATE
INITIATEBuy
Aug 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$20.0M
bought · 2 insiders
$0
sold · 0 insiders
+15.7%
vs their $18.00 cost
DateInsiderTypeValue
Jun 22, 2026
HOMBACH ROBERT J.
Director
BUY$235.8K
May 4, 2026
Loebel Antony
Chief Medical Officer
CONVERT20,109 sh
May 4, 2026
Loebel Antony
Chief Medical Officer
CONVERT63,157 sh
May 4, 2026
ARCH Venture Partners XII, LLC
10%+ Owner
CONVERT2,513,686 sh
May 4, 2026
ARCH Venture Partners XII, LLC
10%+ Owner
CONVERT2,513,686 sh
May 4, 2026
ARCH Venture Partners XII, LLC
10%+ Owner
BUY$19.8M
May 4, 2026
ARCH Venture Partners XII, LLC
10%+ Owner
CONVERT2,681,265 sh
May 4, 2026
PAUL STEVEN M
Director
CONVERT67,031 sh

Earnings setup

Estimates
−$0.56
EPS estimate, this quarter
+2%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.56-$0.63–-$0.50+1.7%$0.00
Next Q-$0.60-$0.77–-$0.47+1.5%$0.00
Current FY-$5.59-$13.10–-$3.76+5.2%$0.00
Next FY-$2.52-$2.99–-$1.98+2.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 3, 2026 SEC
Seaport Therapeutics reported Q2 2026 results: net loss of $62.6M ($1.78/share) versus consensus of -$0.71, a miss…
8-K — Impact 5/10
Jul 31, 2026 Short interest report
Short Interest: SPTX up 39% to 2.8M shares
Settlement 2026-07-31 | Days to cover: 30.75 | ≈5.15% of shares outstanding (est.)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — NEW
2,178,642 shares ($47.3M)
Jun 30, 2026 Inst.
CANADA PENSION PLAN INVESTMENT — NEW
1,975,791 shares ($42.9M)
Jun 22, 2026 Insider
HOMBACH ROBERT J. bought 13,000 shares
Director @ $18.14 ($235.8K)
Jun 8, 2026 SEC
Seaport Therapeutics reported Q1 2026 earnings with a net loss of $25.4M ($10.34/share), widening from $13.1M…
8-K — Impact 4/10
May 6, 2026 SEC
General Atlantic entities filed Form 3 initial beneficial ownership disclosures for Seaport Therapeutics (SPTX)…
3 — Impact 3/10
May 4, 2026 Insider
Loebel Antony acquired 20,109 shares
Chief Medical Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 31, 2026
Short interest
Short Interest: SPTX up 39% to 2.8M shares
Settlement 2026-07-31 | Days to cover: 30.75 | ≈5.15% of shares outstanding (est.)
Jul 15, 2026
Short interest
Short Interest: SPTX down 29% to 2.0M shares
Settlement 2026-07-15 | Days to cover: 12.28 | ≈3.70% of shares outstanding (est.)
Jun 30, 2026
Short interest
Short Interest: SPTX up 43% to 2.8M shares
Settlement 2026-06-30 | Days to cover: 7.67 | ≈5.19% of shares outstanding (est.)
May 4, 2026
Short interest
FTD: SPTX — 29,083 shares ($0.6M) failed to deliver
Settlement: 20260504, Price: $19.84, FTD Value: $577,006.72, SEAPORT THERAPEUTICS INC COM

SecBot reports

10 filings · 2 bullish · 0 bearish · 8 neutral
All SPTX filing & press-release reports (10)